Hospital

From newsworthy moments to groundbreaking research, these were the most-read respiratory syncytial virus-related articles on Pharmacy Times in 2023.

In a study, most patients had specified SBP targets of less than 160 mmHg and all patients attained goal within a relatively short period of time.

With gastrointestinal-based adverse effectss for rivastigmine and other cholinesterase inhibitors, a weight of <50 and <55 kg respectively leads to an increased risk for toxicities.

The drug is the first medicine to be approved for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis that can be self-administered.

One could also argue that the Great Resignation is an era for a great realignment. During lockdown, many individuals took the time to realign their priorities.

This latest revision introduces a new set of drug criteria, refines the existing ones, and enhances the overall formatting to ensure increased ease of use and clarity for its recommendations.

Controlled substance transfers are occurring at a higher rate as health systems create their own ecosystems to combat medication shortages.

The investigators note that psilocybin’s effectiveness in treating depressive symptoms and the positive reception among patients with cancer are encouraging continued research.

The biosimilars landscape is set to witness significant growth, particularly in therapeutic areas like ophthalmology and immunology, with a focus on blockbuster biologics like Humira, Stelara, and Eylea.

The cost of defending license matters and malpractice claim costs have increased over a 5-year period (2017-2022).

Pharmacists play a vital role in HIV care by addressing social determinants of health, managing complex HIV medication regimens, and providing comprehensive patient counseling.

The study included data on ventilator-associated pneumonia and nonventilator hospital-acquired pneumonia, finding lower rates associated with daily toothbrushing.

Tune in to this episode of Public Health Matters for a captivating exploration of global public health through the lens of a pharmacist and traveler.

These drugs have interesting mechanisms, unique use, or may support expanded indications in the future.

The results of the study show the importance of considering neighborhood-level disparities to address and improve medication adherence, according to investigators.

Individuals received 4 daily short messages that reminding them to participate in self-care, active engagement, and early intervention for the first 30 days of the study.

Investigators aim to find a substitution for incomplete Freund adjuvant, which is not suitable for use in humans but shows a strong response to antigen-specific systemic immune responses.

Preclinical data showed that LP-184 shrunk tumors in vivo by more than 90% in just 8 weeks.

Language gaps resulted in barriers and underdiagnosing in children with common allergies, limiting support for these patients and their families.

This approval makes birch triterpenes the first treatment for wounds associated with junctional epidermolysis bullosa to be approved by the FDA.

If approved, V116 would offer significant improvements in safety and effectiveness for the prevention of pneumococcal disease.

Amiodarone also provides pan-variant protection against toxins, a potentially growing area of research in C. difficile infection treatment.

The study authors note that interventions to reverse frailty, such as screening and assessments to identify issues, can help in the management of COPD and asthma and lead to better prognoses.

Previously, garadacimab was granted an orphan drug designation as a therapy for hereditary angioedema by both the FDA and EMA.

Less than 1% of individuals developed Clostridioides difficile infection (CDI), but for those who previously had a CDI the year before, 12% developed a new infection.

Treatment options can be limited for this patient population.

Fran Gregory, PharmD, MBA, vice president of emerging therapies at Cardinal Health, discusses the dynamic landscape of the biosimilars market, providing key insights into its current status and future projections.

Using information from clinical studies and her experiences working in the field, Stephanie Kirk describes treatment options that are on the horizon, and how removing stigma is key in HIV care.

In the study, a new policy empowered unit-based pharmacists to evaluate the patient’s needs and, when safe, switch from a PPI to an H2 blocker.

The approval marks the first for an alternative to platinum-containing chemotherapy.